Role of Vitagliptin and Vitamin D in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)
Status:
Unknown status
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
Sedentary lifestyle and poor dietary choices are leading to a weight gain epidemic and
increasing the risk for developing nonalcoholic fatty liver disease (NAFLD). The strong
relationship between insulin resistance and NAFLD suggests that adding Vitamin D TO insulin
sensitizing therapies such as Galvus (vitagliptin) might be beneficial in the prevention or
improvement in NAFLD. Considering the close relationship between NAFLD and T2DM and lipid
metabolism, we assume that adding vitamin D to Galvus, may be effective for NAFLD by
improving lipid metabolism and by improving type 2 diabetes mellitus (T2DM).